BioSpace News Archive

Atrion Corporation announced the election of Jeannette Bankes as a director, effective immediately.

SpyBiotech announced that the company has filed a clinical trial application with the U.K. Medicines and Healthcare products Regulatory Agency to evaluate SPYVLP01, a vaccine targeting human cytomegalovirus using its Hepatitis B virus-like-particle platform technology.

CMR Surgical has announced that its next-generation Versius® Surgical Robotic System has been used to perform more than 15,000 surgeries globally.

Merck announced the U.S. Food and Drug Administration has accepted for priority review a new supplemental Biologics License Application seeking approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with external beam radiotherapy plus concurrent chemotherapy, followed by brachytherapy as treatment with definitive intent for newly diagnosed patients with high-risk locally advanced cervical cancer.

Theratechnologies Inc. today announced that Mr. Paul Lévesque, President and Chief Executive Officer, will participate in a panel presentation at the Cantor Fitzgerald Global Healthcare Conference 2023 being held September 26-28 in New York City.

Regulus Therapeutics Inc. today announced positive topline results from the first cohort of patients in its Phase 1b MAD study of RGLS8429 for the treatment of ADPKD.

Rezo Therapeutics today announced the appointment of Nadir Mahmood, Ph.D., as chief executive officer and board member.

Ovid Therapeutics Inc. today announced that management will participate in a panel presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26, 2023, at 9:55 a.m. ET in New York, New York.

The Centre for Ion Beam Applications (CIBA), a multidisciplinary research centre at the National University of Singapore (NUS), has recently been designated as an International Atomic Energy Agency (IAEA) Collaborating Centre for Research and Development of Accelerator Science and Multidisciplinary Applications.

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced data from two radiolabeling studies that validate the tumor targeting attributes associated with albumin binding by the FHAB technology.